NBP, US44975P1030

NovaBridge stock: Visara starts ASCEND trial in wet AMD

Published on 11/19/2026 at 04:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
NovaBridge stock gains a clinical milestone as Visara doses the first patient in its ASCEND study. The trial compares VIS-101 with aflibercept in China.

Clinical milestone in wet AMD

  • ASCEND is testing VIS-101 against aflibercept in a randomized Phase 2b study in China.
  • The trial is designed to guide dose selection for a global Phase 3 program planned as early as 2027.
NBP, US44975P1030, Illustration mit AI erstellt.

NovaBridge Biosciences' majority-owned subsidiary Visara has dosed the first patient in ASCEND, a randomized Phase 2b study of VIS-101 for wet age-related macular degeneration. The company announced the milestone on Wednesday, November 18, 2026, in a GlobeNewswire release.

Trial targets longer treatment intervals

ASCEND is expected to enroll approximately 244 treatment-naive patients in China. It compares 6 mg and 9 mg doses of VIS-101 with 2 mg aflibercept, an established anti-VEGF treatment, in a head-to-head design.

After three monthly loading doses, the protocol allows retreatment based on prespecified criteria and evaluates treatment intervals of up to seven months. The study is intended to determine which dose or doses should advance into global Phase 3 development.

Phase 2a results set context

Visara said approximately 50% of patients in the 6 mg treatment-naive cohort of its Phase 2a study remained retreatment-free six months after the last loading dose. ASCEND is designed to test whether that durability can be reproduced in a larger controlled study.

VIS-101 is a tetravalent bispecific inhibitor of VEGF-A and ANG-2 being developed for retinal vascular diseases, including wet AMD, diabetic macular edema and retinal vein occlusion. Visara said a global Phase 3 program could begin as early as 2027.

NovaBridge's business and peers

NovaBridge is a clinical-stage biopharmaceutical company developing differentiated therapies for significant unmet needs. Its portfolio covers oncology and ophthalmology, led by givastomig in gastrointestinal cancers and Visara's retinal and ocular programs. The company is based in the United States and uses clinical development, financing and partnering strategies to advance its pipeline.

NovaBridge Biosciences at a glance

  • Company: NovaBridge Biosciences
  • ISIN: US44975P1030
  • Ticker: NBP
  • Exchange: Nasdaq
  • Focus: Clinical-stage biopharmaceutical development
  • Key program: VIS-101 in wet AMD

The Euro Stoxx 50 provides a broader view of European market conditions for investors following international biotechnology shares.

More news and analyses on NovaBridge Biosciences stock are available here.

Disclaimer...
en | US44975P1030 | NBP | boerse | 70533551 | bgmi